Search results
Best Medicare Part D Prescription Drug Plans in 2024 - NerdWallet
Nerdwallet· 4 days agoThese Medicare Part D plans stand out for member satisfaction and low premiums.
Gateway - Quartz
Quartz· 21 minutes agoAfter dominating the market for weight loss drugs, Ozempic maker Novo Nordisk has set its sights on tackling treatments for heart disease next. Cardior, a Germany-based drug maker, develops ...
Biden plan to save Medicare patients money on drugs risks empty shelves, pharmacists say
San Jose Mercury News· 3 days agoMonths into a new Biden administration policy intended to lower drug costs for Medicare patients,...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Missouri Independent via Yahoo News· 9 hours agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
TONI SAYS: Enrolling in Medicare over 65 with health issues
Odessa American· 5 days agoThe cornerstone of Medicare planning at the Toni Says offices is discussing Medicare Part D prescription drug planning ...
Fact check: Trump falsely claims Biden didn’t lower Americans’ insulin costs
CNN via AOL· 3 days agoTrump’s policy didn’t Biden’s policy, which took effect in 2023, requires every prescription drug ...
Here are four reasons Medicare drug-price 'negotiation' in NJ isn't truly a negotiation.
App.com | Asbury Park Press via Yahoo News· 4 days agoFor 2024, New Jersey seniors had access to about 20 standalone Medicare Part D prescription drug...
Weight Loss Drugs and Medicare: What You Need to Know
TheStreet.com· 4 days agoMore weight loss drugs have been approved for coverage by Medicare, but what are the challenges potential users face? Medicare has recently approved coverage of GLP-1 drugs such as Wegovy to address hypertension.
States urge Supreme Court to review PBM case
Modern Healthcare· 6 days agoDistrict Court for the Western District of Oklahoma granted the trade group a partial win in 2022, ruling that federal law around employer-sponsored coverage was not applicable but ...
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
CNBC· 7 hours agoSkyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new...
